Why is Cardiff Oncology stock surging today?

Cardiff Oncology (CRDF) stock rose 25% after FDA granted Fast Track designation to onvansertib for treating KRAS- or NRAS-mutated metastatic colorectal cancer. The designation is based on Phase 2 trial data showing a 72.2% response rate. CEO Mani Mohindru is presenting at the UBS Global Biopharma Conference. The stock's surge contrasts with a broader market decline.

Original reporting
Published Nov 16, 2026, 3:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 3:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$CRDF
Bullish
high confidence
Mentioned
$CRDF
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CRDFBullishHigh
01

Why it matters

The regulatory win validates the company's pipeline and may accelerate future trial enrollments.

02

Market read

A rare, material regulatory event for a small‑cap biotech, driving a sharp price move.

03

What to watch

Potential competition from other KRAS inhibitors and the need for FDA approval beyond Fast Track.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Cardiff Oncology announced FDA Fast Track for its lead drug onvansertib in metastatic colorectal cancer.

Company-level read

Ticker impact

$CRDFBullishHigh confidence
Context

FDA granted Fast Track designation to onvansertib, driving a 25% pre‑market surge.

Expected impact

upward pressure as investors price in the regulatory milestone.

Evidence & confidence

The designation is a primary disclosure with material impact and the stock already jumped 25%.

Market effects

Highlights momentum in biotech firms pursuing Fast Track pathways for oncology drugs.

May boost broader US biotech sector sentiment despite a weak overall market.

Sets a precedent for similar KRAS/NRAS‑mutated cancer therapies worldwide.

Counterpoint

If the Phase 2 data fails to translate into later‑stage success, the rally could be short‑lived.

Key entities

  • Cardiff Oncology Inc

    Biotech firm developing onvansertib.

  • FDA

    U.S. Food and Drug Administration granting Fast Track status.

Related articles

$CRDFMed

Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms All patients remaining in t

$CRDFMedAI 8/10

FDA grants orphan drug status to Cardiff’s onvansertib for CMML

Cardiff Oncology (CRDF) received FDA Orphan Drug Designation for onvansertib to treat chronic myelomonocytic leukemia (CMML). The drug showed preliminary efficacy in a Phase 1 trial, with benefits including platelet response and stable disease. Orphan Drug Designation offers tax credits, fee exemptions, and market exclusivity. CRDF is developing onvansertib for other cancers as well.

$CRDFMed

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated m

$CRDFMedAI 8/10

Cardiff Oncology Announces $10 Million Registered Direct Offering

Cardiff Oncology (Nasdaq: CRDF) announced a $10 million registered direct offering. It will sell 8,571,429 common shares with warrants at $1.05 per share, plus insider participation of 731,707 shares at $1.435 per share. Warrants exercise at $1.31, exercisable after six months and stockholder-authorized share increase. Closing expected July 16, 2026.